The biotech, which has been working towards commercial development of its IP since March 2022, is targeting ASX quotation in ...

Relay Therapeutics faces challenges with limited clinical data and high expenses but shows promise with their 4D drug design ...

The initial public offering (IPO) of Onyx Biotec Limited ended on Monday, November 18, with a strong subscription, fuelled by ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

With less than US$800mil raised in the subsequent six months, the industry’s proportion of US IPO proceeds has declined to 6.5% from 17% through February, the data showed. The Nasdaq Biotech ...

With an anticipated strong IPO market in 2025 ... benchmark by 150 percentage points (see more details here). Legend Biotech Corp. (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company ...

Two new biotech companies – Vitrafy and Renerve – listed today, breaking an eight-month drought of life sciences IPOs on the ASX. Coincidentally, both have FDA-approved products. A provider of ...

Biotech investors will ... HaemaLogiX’s preliminary view is that it will raise $50m as part of next year’s IPO. HaemaLogiX, in its current form, has so far raised $24.1m.

In this article, we are going to take a look at where Legend Biotech Corp. (NASDAQ ... companies that have been hesitant to pursue IPOs in 2025, capitalizing on the positive market reaction ...

we are going to take a look at where Legend Biotech Corp. (NASDAQ:LEGN) stands against the other up and coming stocks. Donald Trump's victory in the recent presidential election is expected to ...